NVDA
NVIDIA Corporation
NVDA has the edge over PLAB overall, supported by stronger fundamentals and stronger modeled upside.
PLAB
Photronics, Inc.
PLAB's outlook is improving, though it still trails on the overall score.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
PLAB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
PLAB's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over PLAB in the historical PE scenario, which offers more potential upside but is not a forecast.
PLAB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 9.9x | $27.88 | — |
| Cheap | 10x | $28.49 | +2.2% |
| Fair | 13x | $37.09 | +33% |
| Forward | 13x | $27.88 | — |
| Expensive | 22x | $62.33 | +124% |
Historical ranges are pointers, not guarantees.
PLAB's PE is in its cheap range at 9.8x. On analysts' estimates for next year's earnings, today's price would be 13x, in its fair range.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
PLAB Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect PLAB's earnings to grow and its profitability to improve, with its revenue holding steady.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over PLAB on earnings, with more consistent year-over-year improvement.
PLAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.09 | -26% |
| Q3 2026 | $2.83 | +61% |
| Q2 2026 | $2.73 | +42% |
| Q1 2026 | $2.34 | -0.4% |
| Q4 2025 | $2.28 | +9.1% |
| Q3 2025 | $1.76 | -22% |
| Q2 2025 | $1.92 | -11% |
| Q1 2025 | $2.35 | +5.9% |
| Q4 2024 | $2.09 | +3% |
PLAB earned $2.83 per share over the past year, up 61% from the year before.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over PLAB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over PLAB on profitability, with a higher operating margin.
PLAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $216M | +2.7% |
| Q2 2026 | $209.9M | -0.5% |
| Q1 2026 | $225.1M | +6.1% |
| Q4 2025 | $215.8M | -3.1% |
| Q3 2025 | $210.4M | -0.3% |
| Q2 2025 | $211M | -2.8% |
| Q1 2025 | $212.1M | -1.9% |
| Q4 2024 | $222.6M | -2.1% |
PLAB's revenue grew through 2022 and has held roughly level since: $216M last quarter, up 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -1.8 points |
| Q2 2026 | 20% | -6.3 points |
| Q1 2026 | 24% | -0.2 points |
| Q4 2025 | 24% | -0.9 points |
| Q3 2025 | 23% | -1.8 points |
| Q2 2025 | 26% | +0.6 points |
| Q1 2025 | 25% | -2 points |
| Q4 2024 | 25% | -3.4 points |
PLAB's operating margin was 21% last quarter, down 1.8 points from the same quarter a year ago.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over PLAB on cash flow, with more consistent year-over-year improvement.
PLAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $39.4M | +56% |
| Q2 2026 | $1.2M | +$30.3M |
| Q1 2026 | $49.6M | +15% |
| Q4 2025 | $20.3M | -19% |
| Q3 2025 | $25.2M | -50% |
| Q2 2025 | -$29.1M | -152% |
| Q1 2025 | $43.3M | +$45.1M |
| Q4 2024 | $25.2M | -54% |
PLAB still generates free cash flow, though less than at its 2022 peak: $110M over the past year.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over PLAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
PLAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -27K shares |
| 1 year | +1.1% | +650K shares |
| 3 years | -5.3% | -3.3M shares |
| 5 years | -4.5% | -2.8M shares |
| Available history | -15% | -10.4M shares |
PLAB has 59M diluted shares, up 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $20.7M |
| Q2 2025 | $72.1M |
| Q1 2025 | $4.6M |
| Q4 2023 | — |
PLAB hasn't bought back shares in the past year.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
PLAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.0x | Net Cash |
| Q2 2026 | -1.9x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q4 2025 | -1.7x | Net Cash |
| Q3 2025 | -1.6x | Net Cash |
| Q2 2025 | -1.8x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -1.9x | Net Cash |
PLAB has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
PLAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 15.9 | Oversold |
PLAB's weekly RSI is 43 (neutral) and its Stochastic is 16 (oversold).
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
PLAB PE vs Technology Sector
| Metric | PLAB | Sector median | Relative |
|---|---|---|---|
| PE | 9.9x | 28x | 65% below |
| PE % | 14 | 35 | 21 pts below |
PLAB has the edge over NVDA on valuation relative to its sector.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
PLAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 3% below |
| 20 week MA | $29.5 | 5.4% below |
| 50 week MA | $34.6 | 19% below |
| 100 week MA | $27.9 | 0.1% below |
| 200 week MA | $25.7 | 8.3% above |
PLAB has fallen below most of its moving averages, though it's still 8.3% above its 200-week average.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over PLAB on returns for 2026, with the stronger performance.
PLAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.8 | $11.0 | -30% |
| 2021 | $11.0 | $18.5 | +68% |
| 2022 | $18.5 | $16.4 | -11% |
| 2023 | $16.4 | $31.4 | +91% |
| 2024 | $31.4 | $23.9 | -24% |
| 2025 | $23.9 | $33.7 | +41% |
| 2026 YTD | $33.7 | $27.9 | -17% |
PLAB has finished lower in three of the last six years. It's down 17% so far in 2026.